Loading…
2 companies · GEL, thousands · columns ordered by revenue
| Line item | Inova In Vitro | JMP |
|---|---|---|
| Total Revenue | 14,133 | 9,032 |
| Total COGS | -9,463 | -7,137 |
| Gross Profit | 4,670 | 1,895 |
| Gross Margin | 33.0% | 21.0% |
| Total Operating Expenses | -767 | -15 |
| EBITDA | 3,903 | 1,880 |
| EBITDA Margin | 27.6% | 20.8% |
| Total D&A | 0 | -45 |
| EBIT / Operating Income | 3,903 | 1,835 |
| Total Interest Income | 21 | — |
| Total Other Income | 30 | 1,272 |
| Profit Before Tax | 3,954 | 3,107 |
| Total Income Tax | 0 | -160 |
| Net Profit / (Loss) | 3,954 | 2,083 |
| Net Margin | 28.0% | 23.1% |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Inova In Vitro | Healthcare Services | 27.6% | 88th pct | 268 |
| JMP | Pharma | 20.8% | 62nd pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.